{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:23:38Z","timestamp":1788279818566,"version":"build-2803163510"},"reference-count":114,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Safety"],"published-print":{"date-parts":[[2023,5,4]]},"DOI":"10.1080\/14740338.2023.2227560","type":"journal-article","created":{"date-parts":[[2023,6,17]],"date-time":"2023-06-17T11:59:42Z","timestamp":1687003182000},"page":"391-406","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Safety of current systemic therapies for nail psoriasis"],"prefix":"10.1080","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5066-5057","authenticated-orcid":false,"given":"Jonathan K.","family":"Hwang","sequence":"first","affiliation":[{"name":"Weill Cornell Medicine, Department of Dermatology, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5913-9304","authenticated-orcid":false,"given":"Shari R.","family":"Lipner","sequence":"additional","affiliation":[{"name":"Weill Cornell Medicine, Department of Dermatology, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,6,20]]},"reference":[{"key":"e_1_3_6_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2022.2044511"},{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.12.031"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1159\/000512688"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18435"},{"issue":"8","key":"e_1_3_6_6_1","first-page":"731","article-title":"A major win for the treatment of nail psoriasis","volume":"16","author":"Lipner SR","year":"2017","unstructured":"Lipner SR. A major win for the treatment of nail psoriasis. J Drugs Dermatol. 2017;16(8):731\u2013732.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-023-00786\u20134"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.01.072"},{"key":"e_1_3_6_9_1","unstructured":"HUMIRA (adalimumab) injection for subcutaneous use. Food and drug administration. Accessed Apr 5 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/125057s410lbl.pdf"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.08.029"},{"key":"e_1_3_6_11_1","unstructured":"INFLIXIMAB for injection for intravenous use. Food and drug administration. Accessed Apr 5 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/103772s5401lbl.pdf"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67566-6"},{"key":"e_1_3_6_13_1","unstructured":"Enbrel (etanercept) Solution for Subcutaneous Use. Food and drug administration. Accessed Apr 5 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/103795s5503lbl.pdf"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14015"},{"key":"e_1_3_6_15_1","unstructured":"CIMZIA (certolizumab pegol) for injection for subcutaneous use. Food and Drug Administration. Accessed Apr 5 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125160s270lbl.pdf"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203696"},{"key":"e_1_3_6_17_1","unstructured":"SIMPONI (gollmumab) Injection solution for subcutaneous use. Food and Drug Administration. Accessed Apr 5 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/125289s0064lbl.pdf"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11180"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24403"},{"key":"e_1_3_6_20_1","volume-title":"StatPearls","author":"Gerriets V","year":"2022","unstructured":"Gerriets V, Goyal A, Khaddour K. Tumor necrosis factor inhibitors. In: StatPearls. Florida, USA: StatPearls Publishing; 2022 Jul 4."},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-013-0053-5"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12198"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.0793"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12981"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2010.519376"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13374"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3545"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2010.04.014"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.09707.x"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14096"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2019.1577817"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2011.47.4.1576692"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18461"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2011.595574"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1179\/1351000213Y.0000000046"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2017.1366006"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2017.1361404"},{"key":"e_1_3_6_38_1","volume-title":"StatPearls","author":"Preuss CV","year":"2022","unstructured":"Preuss CV, Quick J. Ixekizumab. In: StatPearls. Florida, USA: StatPearls Publishing; 2022 Sep 21."},{"key":"e_1_3_6_39_1","unstructured":"TALTZ (ixekizumab) injection for subcutaneous use. Food and drug administration. Accessed Apr 5 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/125521s014lbl.pdf"},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209709"},{"key":"e_1_3_6_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31429-0"},{"key":"e_1_3_6_42_1","volume-title":"StatPearls","author":"Golbari NM","year":"2023","unstructured":"Golbari NM, Basehore BM, Zito PM. Brodalumab. In: StatPearls. Florida, USA: StatPearls Publishing; 2023 Mar 7."},{"key":"e_1_3_6_43_1","unstructured":"SILIQ\u2122 (brodalumab) injection for subcutaneous use. Food and drug administration. Accessed Apr 5 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761032lbl.pdf"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1749546"},{"key":"e_1_3_6_45_1","volume-title":"StatPearls","author":"Aboobacker S","year":"2022","unstructured":"Aboobacker S, Kurn H, Al Aboud AM. Secukinumab. In: StatPearls. Florida, USA: StatPearls Publishing; 2022 Jul 6."},{"key":"e_1_3_6_46_1","unstructured":"COSENTYX (secukinumab) injection for subcutaneous use. Food and drug administration. Accessed Apr 5 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/125504s043lbl.pdf"},{"key":"e_1_3_6_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17351"},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2020.1679625"},{"key":"e_1_3_6_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13927"},{"key":"e_1_3_6_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14033"},{"key":"e_1_3_6_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16050"},{"key":"e_1_3_6_52_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.993057"},{"key":"e_1_3_6_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15015"},{"key":"e_1_3_6_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16073"},{"key":"e_1_3_6_55_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217927"},{"key":"e_1_3_6_56_1","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2020-2-1"},{"key":"e_1_3_6_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.04.010"},{"key":"e_1_3_6_58_1","doi-asserted-by":"publisher","DOI":"10.2147\/PTT.S328575"},{"key":"e_1_3_6_59_1","unstructured":"STELARA (ustekinumab) injection for subcutaneous or intravenous use. Food and Drug Administration. Accessed Apr 5 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/761044lbl.pdf"},{"key":"e_1_3_6_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12632"},{"key":"e_1_3_6_61_1","unstructured":"TREMFYA (guselkumab) injection for subcutaneous use. Food and drug administration. Accessed Apr 5 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761061s000lbl.pdf"},{"key":"e_1_3_6_62_1","unstructured":"SKYRIZI (risankizumab-rzaa) injection for subcutaneous use. Food and drug administration. Accessed Apr 5 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761105s014lbl.pdf"},{"key":"e_1_3_6_63_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221019"},{"key":"e_1_3_6_64_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11092631"},{"key":"e_1_3_6_65_1","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.6828"},{"key":"e_1_3_6_66_1","doi-asserted-by":"publisher","DOI":"10.1159\/000524199"},{"key":"e_1_3_6_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.02.057"},{"key":"e_1_3_6_68_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15653"},{"key":"e_1_3_6_69_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16866"},{"key":"e_1_3_6_70_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2022.2132143"},{"key":"e_1_3_6_71_1","doi-asserted-by":"publisher","DOI":"10.2165\/11595940-000000000-00000"},{"key":"e_1_3_6_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.09.020"},{"issue":"3","key":"e_1_3_6_73_1","first-page":"300","article-title":"An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up","volume":"11","author":"Reich K","year":"2012","unstructured":"Reich K, Papp KA, Griffiths CE, et al. An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up. J Drugs Dermatol. 2012;11(3):300\u2013312.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_6_74_1","unstructured":"Clinical Guideline Flowchart for Treating Psoriasis Patients Using Biologics. Quality innovation center. Accessed Apr 5 2023. https:\/\/assets.ctfassets.net\/1ny4yoiyrqia\/1t1UWXLsQE9WwJMHI5KITJ\/3ff35149322a33e18775fc6eb750beb0\/AAD-SupplementTable-TreatmentPath.pdf"},{"key":"e_1_3_6_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.11.057"},{"key":"e_1_3_6_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.06.056"},{"key":"e_1_3_6_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.08.049"},{"key":"e_1_3_6_78_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2023.2173170"},{"key":"e_1_3_6_79_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2022.2089020"},{"key":"e_1_3_6_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2020.12.011"},{"key":"e_1_3_6_81_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1744562"},{"key":"e_1_3_6_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.09.001"},{"key":"e_1_3_6_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.02.044"},{"key":"e_1_3_6_84_1","unstructured":"OTEZLA (apremilast) tablets for oral use. Food and drug administration. Accessed Apr 5 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/205437s011lbl.pdf"},{"key":"e_1_3_6_85_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-11-82"},{"key":"e_1_3_6_86_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-022-01235-7"},{"key":"e_1_3_6_87_1","doi-asserted-by":"publisher","DOI":"10.25251\/skin.7.supp.109"},{"key":"e_1_3_6_88_1","volume-title":"StatPearls","author":"Padda IS","year":"2023","unstructured":"Padda IS, Bhatt R, Parmar M. Tofacitinib. In: StatPearls. Florida, USA: StatPearls Publishing; 2023 Jan 17."},{"key":"e_1_3_6_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.01.053"},{"key":"e_1_3_6_90_1","unstructured":"XELJANZ (tofacitinib) tablets for oral use. Food and drug administration. Accessed Apr 5 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/203214s018lbl.pdf"},{"key":"e_1_3_6_91_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2018.1512404"},{"key":"e_1_3_6_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.03.023"},{"key":"e_1_3_6_93_1","doi-asserted-by":"publisher","DOI":"10.1159\/000503062"},{"key":"e_1_3_6_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32127-4"},{"key":"e_1_3_6_95_1","unstructured":"METHOTREXATE tablets for oral use. Food and Drug Administration. Accessed Apr 5 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/040054s015 s016 s017.pdf"},{"key":"e_1_3_6_96_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110242"},{"key":"e_1_3_6_97_1","unstructured":"NEORAL\u00ae Soft Gelatin Capsules (cyclosporine capsules USP). Food and drug administration. Accessed Apr 5 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/050715s035 050716s038lbl.pdf"},{"key":"e_1_3_6_98_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200104270-00006"},{"key":"e_1_3_6_99_1","volume-title":"StatPearls","author":"Zito PM","year":"2022","unstructured":"Zito PM, Mazzoni T. Acitretin. In: StatPearls. Florida, USA: StatPearls Publishing; 2022 Sep 25."},{"key":"e_1_3_6_100_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2008.600"},{"key":"e_1_3_6_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.06.057"},{"key":"e_1_3_6_102_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2020.12.012"},{"key":"e_1_3_6_103_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.16333"},{"key":"e_1_3_6_104_1","doi-asserted-by":"publisher","DOI":"10.1159\/000520469"},{"key":"e_1_3_6_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.01.043"},{"key":"e_1_3_6_106_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.16253"},{"key":"e_1_3_6_107_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19110"},{"key":"e_1_3_6_108_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2022.101809"},{"key":"e_1_3_6_109_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-022-00720-0"},{"key":"e_1_3_6_110_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00126-4"},{"key":"e_1_3_6_111_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00125-2"},{"key":"e_1_3_6_112_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102388"},{"key":"e_1_3_6_113_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102383"},{"key":"e_1_3_6_114_1","unstructured":"UCB announces FDA acceptance of bla resubmission for bimekizumab. UCB. Accessed Apr 5 2023. https:\/\/www.ucb.com\/stories-media\/Press-Releases\/article\/UCB-Announces-FDA-Acceptance-of-BLA-Resubmission-for-Bimekizumab"},{"key":"e_1_3_6_115_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18611"}],"container-title":["Expert Opinion on Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14740338.2023.2227560","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T08:18:54Z","timestamp":1700122734000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14740338.2023.2227560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,4]]},"references-count":114,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5,4]]}},"alternative-id":["10.1080\/14740338.2023.2227560"],"URL":"https:\/\/doi.org\/10.1080\/14740338.2023.2227560","relation":{},"ISSN":["1474-0338","1744-764X"],"issn-type":[{"value":"1474-0338","type":"print"},{"value":"1744-764X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-04-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}